Pulmonary Arterial Hypertension

Endothelial Colony Forming Cells in PAH Restore Myocardial Vascular Density

Endothelial Colony Forming Cells in PAH Restore Myocardial Vascular Density

By

In patients with pulmonary arterial hypertension, endothelial colony forming cell transplantation was associated with restoration of myocardial vascular density.

Inhaled Dry Powder Formulation of Treprostinil Well Tolerated in PAH

Inhaled Dry Powder Formulation of Treprostinil Well Tolerated in PAH

By

LIQ861, an inhaled dry powder formulation of treprostinil, was well tolerated in patients with pulmonary arterial hypertension at a 2-week time point in the phase 3 clinical trial, INSPIRE.

Elevated Myocardial T1 Associated With Increased Septal Angle in PAH

Elevated Myocardial T1 Associated With Increased Septal Angle in PAH

By

Elevated levels of myocardial native T1 are associated with increased interventricular septal angle in patients with pulmonary hypertension.

PAH: An Under-Recognized Complication of Adult-Onset Still's Disease

PAH: An Under-Recognized Complication of Adult-Onset Still's Disease

PAH is an under-diagnosed complication of adult-onset Still disease.

Prognostic Relevance of Cardiopulmonary Exercise Testing in Low-Risk Pulmonary Arterial Hypertension

Prognostic Relevance of Cardiopulmonary Exercise Testing in Low-Risk Pulmonary Arterial Hypertension

By

Combinations of VO2 and change in CI during follow-up visits are valuable prognosis markers in low-risk patients with PAH.

Systemic Sclerosis-Associated PAH Genomic Signature Differs From ILD

Systemic Sclerosis-Associated PAH Genomic Signature Differs From ILD

By

Systemic sclerosis-associated pulmonary hypertension and systemic sclerosis-associated interstitial lung disease exhibit similar but distinct gene expression profiles.

Treprostinil May Have Antithrombotic Effect in Pediatric Pulmonary Hypertension

Treprostinil May Have Antithrombotic Effect in Pediatric Pulmonary Hypertension

By

Treatment with treprostinil has demonstrated potential antithrombotic mechanisms of action in pediatric patients with pulmonary arterial hypertension.

Patient Age Linked With Specific PAH Clinical Profile and Prognosis

Patient Age Linked With Specific PAH Clinical Profile and Prognosis

By

Patients with pulmonary hypertension age ≥65 years have worse long-term survival compared with younger patients.

PAH Survival May Increase Risk for Pulmonary Artery Aneurysms

PAH Survival May Increase Risk for Pulmonary Artery Aneurysms

By

The time course of pulmonary arterial hypertension was an independent risk factor for pulmonary artery aneurysms.

Comorbid Mental Disorder Prevalence Higher in Pulmonary Arterial Hypertension

Comorbid Mental Disorder Prevalence Higher in Pulmonary Arterial Hypertension

By

People with pulmonary arterial hypertension display higher levels of depression and anxiety than previously estimated by healthcare workers.

Pulmonary Hypertension Screening Adaptations for Adult Congenital Heart Disease Subtypes

Pulmonary Hypertension Screening Adaptations for Adult Congenital Heart Disease Subtypes

By

Because standardized approaches for echocardiographic screening are impractical for certain subgroups of people with congenital heart disease, experts offered screening adaptations for pulmonary hypertension.

Pulmonary Thromboendarterectomy Curative for CTEPH Linked to APS

Pulmonary Thromboendarterectomy Curative for CTEPH Linked to APS

By

Pulmonary thromboendarterectomy appears to be a curative resolution in patients with antiphospholipid syndrome related to chronic thromboembolic pulmonary hypertension.

Exercise Oxygen Desaturation, Pulmonary Function Predict Outcomes in SSc-PH

Exercise Oxygen Desaturation, Pulmonary Function Predict Outcomes in SSc-PH

By

Factors associated with a higher risk for mortality included male sex, exercise desaturation, and diffusing capacity of the lungs for carbon monoxide <50%.

Follow-Up Hemodynamics in Systemic Sclerosis-PAH Associated With 1-Year Outcomes

Follow-Up Hemodynamics in Systemic Sclerosis-PAH Associated With 1-Year Outcomes

By

At follow-up, the 6-minute walk distance, cardiac index, stroke volume index, and other hemodynamic variables were independently associated with transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension.

RV Hemodynamics Improved With Riociguat in Pulmonary Arterial Hypertension

RV Hemodynamics Improved With Riociguat in Pulmonary Arterial Hypertension

By

Riociguat was associated with increases in right ventricular work, right ventricular work index, stroke volume index, stroke volume index, and cardiac efficiency in patients with pulmonary arterial hypertension.

High Treprostinil Doses Delay PAH-Related and All-Cause Hospitalizations

High Treprostinil Doses Delay PAH-Related and All-Cause Hospitalizations

By

Higher doses of treprostinil significantly delayed time to first pulmonary arterial hypertension-related or all-cause hospitalization.

Generic Version of Adcirca Now Available for Pulmonary Arterial Hypertension

Generic Version of Adcirca Now Available for Pulmonary Arterial Hypertension

By

Tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, is indicated to treat pulmonary arterial hypertension to improve exercise ability.

Orenitram Decreased Risk of Morbidity/Mortality Event in PAH Trial

Orenitram Decreased Risk of Morbidity/Mortality Event in PAH Trial

By

United Therapeutics announced that the Phase 3 trial of Orenitram for PAH has met its primary endpoint of delayed time to first clinical worsening event.

Segmental Pulmonary Hypertension: Management of New Classification

Segmental Pulmonary Hypertension: Management of New Classification

By

Segmental pulmonary hypertension can result from several conditions, such as complex pulmonary atresia, hemitruncus arteriosus, absence/atresia of a single pulmonary artery, and an anomalous pulmonary artery from the aorta feeding a single lung segment.

Implantable System for Remodulin Approved for Patients With PAH

Implantable System for Remodulin Approved for Patients With PAH

By

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension.

VTE Increases Risk for Chronic Thromboembolic Pulmonary Hypertension

VTE Increases Risk for Chronic Thromboembolic Pulmonary Hypertension

By

A number of risk factors were associated with chronic thromboembolic pulmonary hypertension, including, age >70 years, female gender, and pulmonary embolism at first venous thromboembolism.

Supplementing Pulmonary Arterial Hypertension Therapy With Nutritional Changes

Supplementing Pulmonary Arterial Hypertension Therapy With Nutritional Changes

By

Current research suggests patients with pulmonary arterial hypertension may benefit from iron and vitamin D supplementation.

Neopterin as a Potential Biomarker in PAH and Inoperable CTEPH

Neopterin as a Potential Biomarker in PAH and Inoperable CTEPH

By

Neopterin was predictive of clinical deterioration in patients with pulmonary arterial hypertension and inoperable CTEPH.

RV Base/Apex Ratio May Help Diagnose Pulmonary Arterial Hypertension in Children

RV Base/Apex Ratio May Help Diagnose Pulmonary Arterial Hypertension in Children

By

Right ventricular base/apex ratio reference values may help clinicians diagnose children with pulmonary arterial hypertension.

Pregnancy in Pulmonary Arterial Hypertension: Improved Patient Counseling Needed

Pregnancy in Pulmonary Arterial Hypertension: Improved Patient Counseling Needed

By

Many healthcare providers reported that they often do not have the time to counsel their patients with pulmonary arterial hypertension on pregnancy risks.

PAH in Congenital Heart Disease: Challenges and Advances

PAH in Congenital Heart Disease: Challenges and Advances

By

Management strategies were discussed for subtypes of PAH-congenital heart disease including Eisenmenger syndrome, PAH with persistent systemic to pulmonary shunts, and PAH with small or coincidental defect or PAH after defect closure.

Worsening Shortness of Breath in Patient With Hypertension, Afib

Worsening Shortness of Breath in Patient With Hypertension, Afib

By

A 72-year-old man with hypertension and paroxysmal atrial fibrillation presents to the emergency department because he has been experiencing worsening shortness of breath.

Age-Obesity Interaction in Pulmonary Arterial Hypertension

Age-Obesity Interaction in Pulmonary Arterial Hypertension

The interaction of age and obesity with respect to survival in pulmonary arterial hypertension showed an increased risk for mortality in young adults who were morbidly obese.

PAH in Systemic Sclerosis Increases Risk for Early Mortality

PAH in Systemic Sclerosis Increases Risk for Early Mortality

By

The majority of deaths in patients with systemic sclerosis-associated pulmonary arterial hypertension occurred within 4 years of diagnosis.

CTEPH Increases Risk for Sleep Disordered Breathing

CTEPH Increases Risk for Sleep Disordered Breathing

By

Precapillary pulmonary hypertension and obstructive sleep apnea may be causative factors for central sleep apnea and pulmonary hypertension, respectively.

Sign Up for Free e-newsletters